$73.1 Million is the total value of Vida Ventures Advisors, LLC's 7 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
DYN | Dyne Therapeutics, Inc. | $25,574,792 | -0.6% | 2,220,034 | 0.0% | 34.99% | +1.2% | |
CNTA | Centessa Pharmaceuticals plcordinary shares | $15,137,499 | +24.2% | 3,931,818 | 0.0% | 20.71% | +26.4% | |
KNTE | Kinnate Biopharma, Inc. | $13,798,575 | +2.5% | 2,207,772 | 0.0% | 18.88% | +4.3% | |
ALLO | Allogene Therapeutics, Inc. | $8,882,925 | -21.5% | 1,798,163 | 0.0% | 12.15% | -20.0% | |
LianBioordinary shares | $4,472,885 | +19.5% | 2,282,084 | 0.0% | 6.12% | +21.7% | ||
KRON | Kronos Bio, Inc. | $4,037,358 | -9.9% | 2,765,314 | 0.0% | 5.52% | -8.2% | |
PRAX | Praxis Precision Medicines, Inc. | $1,188,959 | -66.0% | 1,469,665 | 0.0% | 1.63% | -65.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-04-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Dyne Therapeutics, Inc. | 14 | Q4 2023 | 37.4% |
Allogene Therapeutics, Inc. | 14 | Q4 2023 | 42.5% |
Kinnate Biopharma, Inc. | 13 | Q4 2023 | 29.3% |
Kronos Bio, Inc. | 13 | Q4 2023 | 20.4% |
Praxis Precision Medicines, Inc. | 12 | Q3 2023 | 33.2% |
Centessa Pharmaceuticals plc | 11 | Q4 2023 | 39.4% |
LianBio | 9 | Q4 2023 | 12.1% |
Homology Medicines, Inc. | 9 | Q3 2022 | 5.2% |
Oyster Pt Pharma Inc | 5 | Q3 2021 | 10.3% |
Assembly Biosciences, Inc. | 4 | Q2 2021 | 4.6% |
View Vida Ventures Advisors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-12 |
13F-HR | 2024-01-05 |
13F-HR | 2023-10-03 |
13F-HR | 2023-07-19 |
13F-HR | 2023-04-13 |
13F-HR | 2023-02-08 |
13F-HR | 2022-10-05 |
13F-HR | 2022-07-15 |
13F-HR | 2022-05-04 |
13F-HR | 2022-02-10 |
View Vida Ventures Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.